AFibE85.2

Last updated on: 11.08.2023

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Hereditary fibrinogen Aα-chain amyloidosis (Aα-chain amyloidosis) is a form of autosomal dominant systemic amyloidosis caused by mutations in the fibrinogen Aα-chain gene (FGA).

Occurrence/EpidemiologyThis section has been translated automatically.

Predominantly Caucasian patients. Rarely Asians.

ManifestationThis section has been translated automatically.

Amyloidoses are a rare and heterogeneous group of diseases characterized by the deposition of abnormally folded proteins in tissues, ultimately leading to organ damage. The deposits are mainly extracellular and can be identified by their affinity for Congo red and their yellow-green birefringence under polarized light. The current classification of amyloid in medical practice is based on the type of amyloid protein. To date, 36 proteins have been identified as amyloidogenic in humans. In clinical practice, it is critical to distinguish between treatable and nontreatable amyloidoses. In addition, amyloidoses with a genetic component must be distinguished from sporadic types and systemic amyloidoses from localized forms.

Determination of amyloid protein type is essential before specific therapy can be initiated.Early diagnosis of hereditary amyloidosis remains a major challenge and requires the involvement of many clinical and laboratory specialties.

Clinical featuresThis section has been translated automatically.

Clinically, the most prominent manifestation in patients with Aα-chain amyloidosis is progressive nephropathy caused by excessive amyloid deposition in the glomeruli. Petechiae of the skin are found regularly.

TherapyThis section has been translated automatically.

Chemotherapy, renal transplantation (Ceglarz K et al. 2023).

LiteratureThis section has been translated automatically.

  1. Ceglarz K et al (2023) Difficulties in the Diagnosis of Fibrinogen Aα-Chain Amyloidosis-Literature Review and Case Report of a Patient After Kidney Transplantation. Transplant Proc 55: 644-648.
  2. Mousson C et al (2006) Successful hepatorenal transplantation in hereditary amyloidosis caused by a frame-shift mutation in fibrinogen Aalpha-chain gene. Am J Transplant 6:632-635.
  3. Picken MM (2020) The pathology of amyloidosis in classification: A review. Acta Haematol 143:322-334.
  4. Yazaki M et al (2018) Hereditary fibrinogen Aα-chain amyloidosis in Asia: Clinical and Molecular Characteristics. Int J Mol Sci 19:320.

Last updated on: 11.08.2023